Details

Autor(en) / Beteiligte

• SANCHEZ, JUAN JOSE GARCIA
• SULTAN, ALYSHAH ABDUL
• ÄRNLÖV, JOHAN
• BATISTA, MARCELO C.
• CABRERA, CLAUDIA
• CARD-GOWERS, JOSHUA
• CHADBAN, STEVE
• CHERTOW, GLENN M.
• DENICOLA, LUCA
• HALIMI, JEAN-MICHEL
• KANDA, EIICHIRO
• LI, GUISEN
• MENNINI, FRANCESCO SAVERIO
• NAVARRO-GONZALEZ, JUAN
• NOLAN, STEPHEN T.
• POWER, ALBERT
• RETAT, LISE
• TANGRI, NAVDEEP
• WEBBER, LAURA
• WISH, JAY
• XU, MICHAEL

Titel

1051-P: Inside CKD: Modeling the Future Global Burden of Chronic Kidney Disease in Patients with Type 2 Diabetes

Ist Teil von

• Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

Ort / Verlag

New York: American Diabetes Association

Erscheinungsjahr

2021

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Introduction: Type 2 diabetes (T2D) is a leading cause of chronic kidney disease (CKD). Future trajectories of CKD prevalence, progression, and outcomes in patients with T2D are key considerations for policy planning and healthcare implementation. Using country-specific patient-level microsimulation, Inside CKD aims to model the global clinical and economic burden of CKD for 2020-2025. Methods: We used the Inside CKD microsimulation to model the clinical burden of CKD in patients with T2D. We constructed virtual populations using country-specific data, including demographics and prevalence of concomitant CKD (by stage) and T2D, from multiple published sources. Results: Preliminary data from three countries demonstrate that in 2020-2025 the number of patients with T2D and CKD is expected to rise by 6.5% in the UK, 13.2% in the US, and 16.6% in Canada (Figure). The largest increase is expected in the 35-64-years age group in the UK (21.8%) and in the ≥ 65-years age group in the US and Canada (16.7% and 21.2%, respectively). Conclusion: This microsimulation models a linear increase in the number of patients with both T2D and CKD over 5 years, including consistent increases in the number of patients with T2D and CKD stages 3b-5. Reliable epidemiologic models can help inform future country-specific healthcare policy and the design of interventions focused on early diagnosis and slowing CKD progression.